13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001388325
Total reported value
$1.7B
$1.7B
22 檔
36.7%
In Q1 2026, Novo Holdings A/S's U.S. equity holdings reached a combined market value of $1.7B, distributed across 22 disclosed stock positions.
In Q1 2026, Novo Holdings A/S adopted a defensive or profit-taking posture, trimming 7 positions and completely liquidating 3 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including EWTX, BN, ASML) accounted for 36.7% of total reported equity market value during Q1 2026.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 13.65% | -1.03% | — | |
| 2 | BN | Brookfield CORP | Stock-Financials | 11.46% | -2.78% | — | |
| 3 | ASML | ASML Holding N.V. | Stock-Tech | 10.16% | +0.81% | -16.67% | |
| 4 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 9.92% | -2.27% | +4.82% | |
| 5 | MPLT | Maplight Therapeutics Inc | Stock-Other | 6.07% | +1.60% | — | |
| 6 | CRM | Salesforce Inc | Stock-Tech | 5.95% | -2.37% | +19.08% | |
| 7 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 4.56% | -1.69% | -4.62% | |
| 8 | ELVN | Enliven Therapeutics Inc | Stock-Other | 4.07% | -1.12% | -13.51% | |
| 9 | PCVX | Vaxcyte Inc | Stock-Other | 4.05% | -1.35% | -6.13% | |
| 10 | PHVS | Pharvaris N.V. | Stock-Other | 4.01% | -1.20% | — | |
| 11 | AVBP | Arrivent Biopharma Inc | Stock-Other | 3.63% | -0.60% | — | |
| 12 | VRDN | Viridian Therapeutics Inc | Stock-Other | 3.17% | -0.89% | -15.97% | |
| 13 | CLDX | Celldex Therapeutics Inc | Stock-Other | 3.08% | -0.87% | — | |
| 14 | APGE | Apogee Therapeutics Inc | Stock-Other | 3.07% | -3.07% | EXIT | |
| 15 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 3.02% | -3.02% | EXIT | |
| 16 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 2.75% | -0.24% | — | |
| 17 | BABA | Alibaba Group Holding-sp Adr | Stock-Consumer Disc | 2.62% | -1.19% | — | |
| 18 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 2.29% | -0.59% | — | |
| 19 | BBOT | Bridgebio Oncology Therapeut | Stock-Other | 1.59% | -0.59% | +11.45% | |
| 20 | VALN | Valneva Se - Adr | Stock-Other | 0.54% | -0.54% | EXIT | |
| 21 | LNZA | Lanzatech Global Inc | Stock-Other | 0.21% | -0.15% | — | |
| 22 | MQ | Marqeta Inc-a | Stock-Other | 0.15% | +0.27% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | EWTX | Edgewise Therapeutics Inc | +3.3% | — | Unchanged |
| 2 | ELVN | Enliven Therapeutics Inc | +2.3% | -13.51% | Trim |
| 3 | MIRM | Mirum Pharmaceuticals Inc | +2.2% | +4.82% | Add |
| 4 | MPLT | Maplight Therapeutics Inc | +1% | — | Unchanged |
| 5 | PCVX | Vaxcyte Inc | +0.8% | -6.13% | Trim |
| 6 | ASML | ASML Holding N.V. | +0.7% | -16.67% | Trim |
| 7 | FDMT | 4d Molecular Therapeutics In | +0.6% | — | Unchanged |
| 8 | AVBP | Arrivent Biopharma Inc | +0.6% | — | Unchanged |
| 9 | CLDX | Celldex Therapeutics Inc | +0.6% | — | Unchanged |
| 10 | PHVS | Pharvaris N.V. | +0.2% | — | Unchanged |
| 11 | LNZA | Lanzatech Global Inc | 0% | — | Unchanged |
| 12 | MQ | Marqeta Inc-a | 0% | — | Unchanged |
| 13 | BMRN | Biomarin Pharmaceutical Inc | 0% | — | Unchanged |
| 14 | APGE | Apogee Therapeutics Inc | -0.3% | -21.05% | Trim |
| 15 | BABA | Alibaba Group Holding-sp Adr | -0.3% | — | Unchanged |
| 16 | BBOT | Bridgebio Oncology Therapeut | -0.3% | +11.45% | Add |
| 17 | CRM | Salesforce Inc | -0.8% | +19.08% | Add |
| 18 | BN | Brookfield CORP | -1% | — | Unchanged |
| 19 | VALN | Valneva Se - Adr | -1% | -54.12% | Trim |
| 20 | CRNX | Crinetics Pharmaceuticals In | -1.3% | -4.62% | Trim |
| 21 | VRDN | Viridian Therapeutics Inc | -2.6% | -15.97% | Trim |
| 22 | ZBIO | Zenas Biopharma Inc | — | EXIT | Sold out |
| 23 | INSM | Insmed Inc | — | EXIT | Sold out |
| 24 | XENE | Xenon Pharmaceuticals Inc | — | NEW | New buy |
| 25 | IOBTQ | Io Biotech Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Novo Holdings A/S reported a total U.S. public equity portfolio value of $1.7B across 22 disclosed positions in Q1 2026.
During Q1 2026, Novo Holdings A/S's top holdings by market value included EWTX (13.7%)、BN (11.5%)、ASML (10.2%). The largest single position, EWTX, represented 13.7% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
XENE
市值: $28.2M
Top Position Liquidated / Trimmed
ZBIO
前期市值: $52.6M
In Q1 2026, Novo Holdings A/S made 14 total portfolio adjustments, initiating 1 new buys, adding to 3 positions, trimming 7 holdings, and fully liquidating 3 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.